固体口服制剂工艺研究员
百奥泰生物科技(广州)有限公司
- 公司规模:150-500人
- 公司性质:合资(欧美)
- 公司行业:制药/生物工程
职位信息
- 发布日期:2017-05-27
- 工作地点:广州
- 招聘人数:3人
- 工作经验:2年经验
- 学历要求:本科
- 职位月薪:1-10000000/年
- 职位类别:生物工程/生物制药
职位描述
职位描述:
岗位职责:
1. 负责药物制剂处方筛选、工艺研究和优化;
2. 完成实验原始记录及实验报告;
3. 协助药物制剂中试放大及生产技术转移;
4. 完成药物制剂研究相关申报资料的整理工作。
入职要求:
1. 药物制剂相关专业本科及以上学历 ;
2. 固体口服制剂工艺或处方研究两年以上工作经验 ;
3. 能熟练操作固体口服制剂制备过程中各种仪器设备;
4. 有较强的分析和解决问题的能力,能够较快的把握问题的关键点及提供行之有效的技术方案;
5. 工作严谨认真,具有良好的沟通和与团队协作能力。
举报
分享
岗位职责:
1. 负责药物制剂处方筛选、工艺研究和优化;
2. 完成实验原始记录及实验报告;
3. 协助药物制剂中试放大及生产技术转移;
4. 完成药物制剂研究相关申报资料的整理工作。
入职要求:
1. 药物制剂相关专业本科及以上学历 ;
2. 固体口服制剂工艺或处方研究两年以上工作经验 ;
3. 能熟练操作固体口服制剂制备过程中各种仪器设备;
4. 有较强的分析和解决问题的能力,能够较快的把握问题的关键点及提供行之有效的技术方案;
5. 工作严谨认真,具有良好的沟通和与团队协作能力。
职能类别: 生物工程/生物制药
关键字: 制剂
公司介绍
百奥泰生物制药股份有限公司(Bio-Thera Solutions, Ltd.)是一家由海外留学归国精英创办的生物制药企业,致力于新一代抗体创新药和生物类似药的研发,用于治疗癌症、自身免疫性疾病、心血管疾病以及其它危及人类生命的重大疾病。
作为新一代抗体药物研发引领者,百奥泰成功搭建了领先的抗体药物技术平台,并建立起丰富的创新药物和生物类似药物产品管线。 在研产品25个,其中8个候选产品处于不同临床阶段。治疗自身免疫疾病的阿达木单抗类似药(原研药为全球“药王”)有望在同类产品中成为中国首仿;治疗心血管疾病的巴替非班是我国第一个针对β3整合素受体的国家1.1类新药。治疗乳腺癌的抗HER2 ADC注射液、治疗多种实体瘤的贝伐珠单抗类似药、治疗自身免疫疾病的托珠单抗类似药已进入Ⅲ期临床。
百奥泰广纳贤才,组建了一支具有丰富生物药物研发和产业化经验的优秀人才队伍。现有员工400余人,硕博士比例高达60%,其中不乏多位资深海外学成归国专家、“千人计划”专家、广东省首批“科技领军人才”、广东省“珠江人才计划”创新创业团队、广州市“百人计划”等优秀成员。
“科学驱动创新,创新只为生命”,百奥泰始终以病人的福祉作为企业的首要核心价值,通过创新研发为病人提供安全、有效、可负担的优质产品,以满足亟待解决的治疗需求。坚持创新,追求卓越,百奥泰部分产品和技术力争成为中国乃至全球的引领者!
Bio-Thera Solutions Ltd, a leading biotechnology company in China, is dedicated to researching and developing innovative and biosimilar therapeutics for the treatment of cancers, autoimmune, cardiovascular diseases, and other serious medical conditions.
Bio-Thera is a leader in next generation antibody discovery and engineering. The company has developed a suite of proprietary technologies for target discovery, antibody engineering and therapeutic development, and antibody manufacturing capability. We have more than 25 research projects, 8 of which are in the clinical stage. BAT1406 was the first adalimumab (global top 1 best-selling drug) biosimilar submitted to CFDA for IND application, and is approaching marketing application submission. BAT2094 is the first class 1.1 new drug targeting β3 integrin in China. Other three programs in late clinical stage are bevacizumab biosimilar for cancer treatment, tocilizumab biosimilar for autoimmune diseases, and BAT8001, an antibody-drug conjugate, targeting HER2 positive cancers.
Bio-Thera built an excellent talent team with biological medicine experience of research and industrialization. The company has nearly 400 staff, the ratio of Master and Dr is as high as 60%, including a number of senior overseas returnee experts, "Thousand Talents Plan" experts, leading talents of Guangdong "Pearl River Talents Plan" innovative entrepreneurial team, "Hundred Talents Plan" experts in Guangzhou and many outstanding members .
"Driven By Science, innovation for life", Bio-Thera has always been to the health of patients as the first core value of enterprise, through innovative research and development for the patient to provide a safe, effective and affordable products, to meet the treatment needs . Persist in innovation and pursue excellence, Bio-Thera’s products and technologies strive to become the leader of China and even the world!
作为新一代抗体药物研发引领者,百奥泰成功搭建了领先的抗体药物技术平台,并建立起丰富的创新药物和生物类似药物产品管线。 在研产品25个,其中8个候选产品处于不同临床阶段。治疗自身免疫疾病的阿达木单抗类似药(原研药为全球“药王”)有望在同类产品中成为中国首仿;治疗心血管疾病的巴替非班是我国第一个针对β3整合素受体的国家1.1类新药。治疗乳腺癌的抗HER2 ADC注射液、治疗多种实体瘤的贝伐珠单抗类似药、治疗自身免疫疾病的托珠单抗类似药已进入Ⅲ期临床。
百奥泰广纳贤才,组建了一支具有丰富生物药物研发和产业化经验的优秀人才队伍。现有员工400余人,硕博士比例高达60%,其中不乏多位资深海外学成归国专家、“千人计划”专家、广东省首批“科技领军人才”、广东省“珠江人才计划”创新创业团队、广州市“百人计划”等优秀成员。
“科学驱动创新,创新只为生命”,百奥泰始终以病人的福祉作为企业的首要核心价值,通过创新研发为病人提供安全、有效、可负担的优质产品,以满足亟待解决的治疗需求。坚持创新,追求卓越,百奥泰部分产品和技术力争成为中国乃至全球的引领者!
Bio-Thera Solutions Ltd, a leading biotechnology company in China, is dedicated to researching and developing innovative and biosimilar therapeutics for the treatment of cancers, autoimmune, cardiovascular diseases, and other serious medical conditions.
Bio-Thera is a leader in next generation antibody discovery and engineering. The company has developed a suite of proprietary technologies for target discovery, antibody engineering and therapeutic development, and antibody manufacturing capability. We have more than 25 research projects, 8 of which are in the clinical stage. BAT1406 was the first adalimumab (global top 1 best-selling drug) biosimilar submitted to CFDA for IND application, and is approaching marketing application submission. BAT2094 is the first class 1.1 new drug targeting β3 integrin in China. Other three programs in late clinical stage are bevacizumab biosimilar for cancer treatment, tocilizumab biosimilar for autoimmune diseases, and BAT8001, an antibody-drug conjugate, targeting HER2 positive cancers.
Bio-Thera built an excellent talent team with biological medicine experience of research and industrialization. The company has nearly 400 staff, the ratio of Master and Dr is as high as 60%, including a number of senior overseas returnee experts, "Thousand Talents Plan" experts, leading talents of Guangdong "Pearl River Talents Plan" innovative entrepreneurial team, "Hundred Talents Plan" experts in Guangzhou and many outstanding members .
"Driven By Science, innovation for life", Bio-Thera has always been to the health of patients as the first core value of enterprise, through innovative research and development for the patient to provide a safe, effective and affordable products, to meet the treatment needs . Persist in innovation and pursue excellence, Bio-Thera’s products and technologies strive to become the leader of China and even the world!
联系方式
- Email:bd@bio-thera.com
- 公司地址:地址:span黄埔区开源大道11号科技企业加速器A6幢5楼